Teva Pharmaceuticals Reduces its Sales and Profit Forecasts

Teva Pharmaceuticals Industries, Ltd. (NASDAQ:TEVA) has reduced the guidance it gave analysts for its sales and profit.  The company has explained this by saying that it has fewer new generic drugs on the market.  The company is forecasting revenue in the range of $18.3 billion to $18.6 billion and earnings in the range of $4.92 to $5.02.  The company had previously forecast revenues of $18.5 to $19 billion and earnings in the range of $4.90 to $5.20 per share.

The company earlier acquired Cephalon (NASDAQ:CEPH) to enhance its portfolio of non-generic medications.  The $6.5 billion acquisition was completed last month and accreted roughly $0.15 per share in earnings to Teva’s bottom line.  More detail can be found here.

Following is some information on the company’s stock price performance, along with that of its competitors.

  • Teva Pharmaceuticals Industries, Ltd. (NASDAQ:TEVA): The shares recently traded at $38.78, down $0.31, or 0.78% ,on the day.  The shares have traded in a 52-week range of $35 to $57.08 and its market capitalization is $34.3 billion.  About the company: Teva Pharmaceuticals Industries, Ltd. develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients.  The Company produces antibiotics, oncological products, Alpha D3 for treatment of post-menopausal bone loss in women and Copaxone for treatment of multiple sclerosis.  Teva develops novel drugs for diseases of the central nervous system.
  • Novartis AG (NYSE:NVS): The shares recently traded at $55.46, up $0.18, or 0.27%, on the day.  The shares have traded in a 52-week range of $52.09 to $64.82 and its market capitalization is $134.14 billion.  About the company: Novartis AG manufactures pharmaceutical and consumer healthcare products.  The Company produces pharmaceuticals for cardiovascular, respiratory and infectious diseases; oncology, neuroscience, transplantation, dermatology, gastrointestinal and urinary conditions, and arthritis; vaccines and diagnostics; vision, and animal health products.
  • Par Pharmaceutical Company (NYSE:PRX): The shares recently traded at $29.80, up $0.13, or 0.44%, on the day.  The shares have traded in a 52-week range of $24.85 to $39.57 and its market capitalization is $1.09 billion.  About the company: Par Pharmaceuticals Cos., Inc. is a manufacturer and distributors of generic drugs.  The Company’s product line consists of prescription and over the counter products in oral dosage form such as tablets, caplets, and two-piece hard-shell capsules, as well as in the semi-solid form of a cream.
  • GlaxoSmithKline plc (NYSE:GSK): The shares recently traded at $43.31, down $0.06, or 0.13%, on the day.  The shares have traded in a 52-week range of $36.28 to $45.68 and its market capitalization is $109.65 billion.  About the company: GlaxoSmithKline plc is a research-based pharmaceutical group that develops, manufactures and markets vaccines, prescription and over-the-counter medicines, as well as health-related consumer products.  The Group, which also provides laboratory testing and disease management services, specializes in treatments for respiratory, central nervous system, gastro-intestinal and genetic disorders.
  • Merck & Co., Inc. (NYSE:MRK): The shares recently traded at $34.19, up $013, or 0.38%, on the day.  The shares have traded in a 52-week range of $29.47 to $37.65 and its market capitalization is $105.33 billion.About the company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products.  Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.

(Note: Selected financial data are sourced from Google Finance.  All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

Check out our analysis of Jim Cramer’s latest stock calls

More from The Cheat Sheet